Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta™ is for the treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T cell therapies lysing CD19-positive targets. Their dramatic efficacy in the short term has been highlighted by many media reports. By contrast, their glaring safety gaps behind the miracles remain much less addressed. Here, we focus on addressing the crucial challenges in relation to the gaps.

FDA最近批准了两种自体嵌合抗原受体（CAR）T细胞疗法（Kymriah™和Yescarta™）。Kymriah™用于治疗难治性或复发性（R / R）B细胞前体急性淋巴细胞白血病的儿科患者和年轻成年人，Yescarta™用于治疗R / R大B细胞淋巴瘤的成年患者。通常，两种都是裂解CD19阳性靶标的CD19特异性CAR T细胞疗法。许多媒体报道都强调了它们在短期内的巨大功效。相比之下，它们在奇迹背后的明显安全漏洞仍然很少得到解决。在这里，我们专注于解决与差距有关的关键挑战。